Treatment Options and Challenges for Patients With Pancreatic Cancer

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.